PR Newswire Clinical TrialsOriginal article
SpliSense Granted EMA EARLY PRIME Designation for SPL84 in Cystic Fibrosis
RegulatorypositiveSPL84Positive
AI Analysis
Summary
SpliSense received EMA PRIME designation for SPL84, an inhaled RNA therapy targeting cystic fibrosis patients with the 3849+10Kb C>T mutation. The company is advancing SPL84 to Phase 2b clinical trials.
Clinical Trial Data
Phase
2b
Outcome Details
Granted EMA PRIME (e-PRIME) designation for inhaled RNA therapy
Importance:7/10
Sentiment:
0.80
EMA PRIME designationSPL84inhaled RNA therapycystic fibrosisPhase 2bunmet medical need
Read the original article
Published by PR Newswire Clinical Trials on March 3, 2026 12:00 PM